PTC Therapeutics (NASDAQ:PTCT) Announces Earnings Results

09 May 2026, 10:51 by Teresa Graham · The Cerbat Gem

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.42, FiscalAI reports. PTC Therapeutics had a negative net margin of 22.58% and a negative return on equity of 362.45%. The firm had revenue of $272.55 million for the quarter, compared to the consensus estimate of $217.42 million. During the same quarter in the previous year, the company earned $10.04 earnings per share. The business’s revenue was up 43.5% compared to the same quarter last year.

Here are the key takeaways from PTC Therapeutics’ conference call:

Record quarter with $273M total revenue and $226M net product revenue; management raised 2026 product revenue guidance to $750M–$850M and total revenue to $1.08B–$1.18B.
Sephience launch accelerating—Q1 Sephience revenue was $125M (36% QoQ), U.S. starts averaging ~140/month, >90% of U.S. PKU centers have prescribed, and commercial roll‑out is planned in up to 30 countries by year‑end with payers covering >2/3 of the U.S. population.
Positive 24‑month PIVOT‑HD interim results for votoplam: the 10 mg dose showed a ~52% slowing of disease progression vs a matched natural history cohort in Stage 2 and a favorable safety profile, supporting the Novartis‑led phase III INVEST‑HD (≈770 pts) now enrolling.
Vatiquinone path forward agreed with FDA: an open‑label, natural‑history‑controlled 24‑month study (≈120 patients, age 7–21, primary mFARS) will be initiated to support NDA resubmission, which management says increases probability of success but requires additional data collection.
Strong liquidity with $1.89B in cash, cash equivalents and marketable securities as of March 31, 2026, which management says supports ongoing R&D, the Sephience launch, and selective accretive business development.

PTC Therapeutics Stock Up 14.3%

PTCT stock traded up $9.20 during midday trading on Friday, reaching $73.69. The stock had a trading volume of 5,836,355 shares, compared to its average volume of 1,147,047. The business has a fifty day simple moving average of $67.69 and a two-hundred day simple moving average of $72.07. The firm has a market cap of $6.11 billion, a price-to-earnings ratio of -31.63 and a beta of 0.53. PTC Therapeutics has a twelve month low of $43.17 and a twelve month high of $87.50.

Insider Transactions at PTC Therapeutics

In other PTC Therapeutics news, EVP Lee Scott Golden sold 829 shares of the firm’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $67.99, for a total transaction of $56,363.71. Following the transaction, the executive vice president owned 79,115 shares in the company, valued at approximately $5,379,028.85. This trade represents a 1.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Stephanie Okey sold 15,167 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $70.00, for a total value of $1,061,690.00. Following the transaction, the director owned 8,000 shares in the company, valued at approximately $560,000. This trade represents a 65.47% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 126,492 shares of company stock valued at $8,634,621. 5.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On PTC Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PTCT. Public Employees Retirement System of Ohio acquired a new stake in shares of PTC Therapeutics during the fourth quarter worth about $126,000. Van ECK Associates Corp acquired a new stake in shares of PTC Therapeutics during the fourth quarter worth about $217,000. CIBC Private Wealth Group LLC acquired a new stake in shares of PTC Therapeutics during the fourth quarter worth about $191,000. Picton Mahoney Asset Management bought a new position in shares of PTC Therapeutics during the fourth quarter worth about $173,000. Finally, LPL Financial LLC bought a new position in shares of PTC Therapeutics during the fourth quarter worth about $225,000.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on PTCT shares. Wells Fargo & Company lifted their target price on shares of PTC Therapeutics from $86.00 to $95.00 and gave the company an “overweight” rating in a research note on Friday. Royal Bank Of Canada lifted their price target on PTC Therapeutics from $81.00 to $82.00 and gave the company a “sector perform” rating in a report on Friday. Bank of America cut their price target on PTC Therapeutics from $97.00 to $93.00 and set a “buy” rating for the company in a report on Friday, February 20th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of PTC Therapeutics in a report on Friday, February 20th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $94.00 price target on shares of PTC Therapeutics in a report on Friday. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $88.36.

Read Our Latest Research Report on PTC Therapeutics

Trending Headlines about PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

Positive Sentiment: PTC Therapeutics reported Q1 revenue of $273 million and EPS of -$0.03, beating Wall Street estimates on both the top and bottom line. Revenue was up 43.5% year over year, and the company said its updated results support a higher full-year 2026 outlook. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Positive Sentiment: The company raised FY 2026 revenue guidance to $1.1 billion-$1.2 billion, above the market’s prior expectation of about $1.0 billion, signaling stronger commercial momentum. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Positive Sentiment: Wells Fargo lifted its price target on PTCT from $86 to $95 and kept an Overweight rating, suggesting further upside if execution continues. Benzinga report on Wells Fargo price target increase
Neutral Sentiment: Royal Bank of Canada raised its price target from $81 to $82 while maintaining a Sector Perform rating, indicating a more measured view than Wells Fargo despite still acknowledging some upside. Benzinga report on RBC price target increase
Neutral Sentiment: Management also highlighted progress in its pipeline and programs, including Sephience launch growth and positive interim data for votoplam, which may support longer-term sentiment but is less immediately impactful than the earnings beat. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

PTC Therapeutics Company Profile

(Get Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.